153 related articles for article (PubMed ID: 17212641)
1. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
[TBL] [Abstract][Full Text] [Related]
2. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
Guedj H; Guedj J; Negro F; Lagging M; Westin J; Bochud PY; Bibert S; Neumann AU;
J Viral Hepat; 2012 Jul; 19(7):488-96. PubMed ID: 22676361
[TBL] [Abstract][Full Text] [Related]
3. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
[TBL] [Abstract][Full Text] [Related]
4. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
5. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
[TBL] [Abstract][Full Text] [Related]
6. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
[TBL] [Abstract][Full Text] [Related]
7. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
Jian Wu Y; Shu Chen L; Gui Qiang W
Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.
AlQaraawi AM; Sanai FM; Al-Husseini H; Albenmousa A; AlSheikh A; Ahmed LR; Hersi A; Al-Otaibi MM; Syed M; Ali SM; Al-hamoudi W; Alswat KA; Abdo AA
Dig Dis Sci; 2011 Apr; 56(4):1222-8. PubMed ID: 20931285
[TBL] [Abstract][Full Text] [Related]
9. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
10. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Romero AI; Lagging M; Westin J; Dhillon AP; Dustin LB; Pawlotsky JM; Neumann AU; Ferrari C; Missale G; Haagmans BL; Schalm SW; Zeuzem S; Negro F; Verheij-Hart E; Hellstrand K;
J Infect Dis; 2006 Oct; 194(7):895-903. PubMed ID: 16960776
[TBL] [Abstract][Full Text] [Related]
11. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.
Sanyal AJ
Liver Int; 2011 Jan; 31 Suppl 1():23-8. PubMed ID: 21205134
[TBL] [Abstract][Full Text] [Related]
12. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a.
Hofer H; Bankl HC; Wrba F; Steindl-Munda P; Peck-Radosavljevic M; Osterreicher C; Mueller C; Gangl A; Ferenci P
Am J Gastroenterol; 2002 Nov; 97(11):2880-5. PubMed ID: 12425563
[TBL] [Abstract][Full Text] [Related]
14. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
[TBL] [Abstract][Full Text] [Related]
17. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
[TBL] [Abstract][Full Text] [Related]
18. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
[TBL] [Abstract][Full Text] [Related]
19. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
Yenice N; Mehtap O; Gümrah M; Arican N
Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
